These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9797754)

  • 1. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.
    Martin RM; Dunn NR; Freemantle SN; Mann RD
    Thorax; 1998 Jul; 53(7):558-62. PubMed ID: 9797754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
    Martin RM; Shakir S
    Drug Saf; 2001; 24(6):475-81. PubMed ID: 11368253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ; Jaeschke R
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006922. PubMed ID: 19588410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-control study of salmeterol and near-fatal attacks of asthma.
    Williams C; Crossland L; Finnerty J; Crane J; Holgate S; Pearce N; Beasley R
    Thorax; 1998 Jan; 53(1):7-13. PubMed ID: 9577515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids.
    Crompton GK; Ayres JG; Basran G; Schiraldi G; Brusasco V; Eivindson A; Jamieson AH; Olsson H
    Am J Respir Crit Care Med; 1999 Mar; 159(3):824-8. PubMed ID: 10051257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007695. PubMed ID: 19821436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can beta agonists cause dilated cardiomyopathy?
    Choudhary AS; Robinson GM
    Heart Lung Circ; 2009 Oct; 18(5):367-9. PubMed ID: 19081299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.
    Mann RD; Kubota K; Pearce G; Wilton L
    J Clin Epidemiol; 1996 Feb; 49(2):247-50. PubMed ID: 8606326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
    Wilson AJ; Gibson PG; Coughlan J
    Cochrane Database Syst Rev; 2000; (2):CD001281. PubMed ID: 10796631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can oral beta2 agonists cause heart failure?
    Jenne JW
    Lancet; 1998 Oct; 352(9134):1081-2. PubMed ID: 9798578
    [No Abstract]   [Full Text] [Related]  

  • 11. Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
    Shah L; Wilson AJ; Gibson PG; Coughlan J
    Cochrane Database Syst Rev; 2003; (3):CD001281. PubMed ID: 12917905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
    Chan J; Hui RL; Spence MM
    J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK.
    Meier CR; Jick H
    Thorax; 1997 Jul; 52(7):612-7. PubMed ID: 9246132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta2 agonists and heart failure.
    Lindmark B; Ottosson A
    Lancet; 1998 Nov; 352(9141):1709-10. PubMed ID: 9853469
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of salmeterol in the maintenance treatment of asthma.
    Nathan RA; Seltzer JM; Kemp JP; Chervinsky P; Alexander WJ; Liddle R; Mills R
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):243-8. PubMed ID: 7552926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review.
    Rodrigo GJ; Moral VP; Marcos LG; Castro-Rodriguez JA
    Pulm Pharmacol Ther; 2009 Feb; 22(1):9-19. PubMed ID: 19026757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
    Bennett JA; Tattersfield AE
    Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
    Cazzola M; Matera MG; Donner CF
    Drugs; 2005; 65(12):1595-610. PubMed ID: 16060696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.